Minimally Invasive Micro Sclerostomy (MIMS®) is a Stentless, simple and fast Glaucoma treatment which effectively lowers the intraocular pressure (IOP) without the need for major invasive surgery.

A Minimal invasive and Stent-less Treatment Glaucoma Innovation

MIMS® is a rapid and minimal invasive procedure at the forefront of interventional glaucoma treatments. Fewer post-op complications allow for effective IOP management. MIMS® is designed to create a sclerostomy similar to trabeculectomy, the gold standard for incisional glaucoma surgery, but with an approach that is less invasive, in terms of tissue damage, and without any implanted material (stent-less). Therefore, complications relating to hyphema and hypotony (such as flat anterior chamber, choroidal effusions and detachments), which are observed in trabeculectomy are expected to occur at a lower incidence and severity with MIMS®. Other post-operative events are expected to be similar to other minimally invasive, stent-less glaucoma treatments.

How MIMS® Works

Minimally Invasive Micro Sclerostomy (MIMS®) is fast, accessible and effective. MIMS® is intended for the reduction of elevated IOP. It works by inserting a specially designed cutting tool into the sclera and removing a small channel of tissue. This channel will remain open and continuously drain, effectively reducing IOP.

MIMS® advantages:

  • A minimal surgical intervention into the eye with the
  • consequent lower risk of hypotony or injury to the surrounding ocular tissues
  • enables stable post-operative IOP levels
  • Takes short surgical time (few minutes)
  • MIMS® application is simple and easy

A Ready-to-Use Surgical System

MIMS® is a lightweight surgical system intended for use by trained professional ophthalmologists. It’s easy to use and learn, intuitive to operate and requires fewer staff to assist in non-surgical environments. A central control touchscreen demonstrates the surgical parameters, and a foot pedal initiates the precise handheld cutting tool movement.

Precision Glaucoma Treatment Technology

Learn more about Sanoculis and MIMS® surgical device innovation.

Outstanding Clinical Performance


Min Procedure


IOP Reduction after 12


Medication reduction
at 12 mo.

ZERO Major/serious intra/post-op ocular complications

Major intra/post-op

MIMS® Testimonials

News & Publications

Global Distribution & Partners




MIMS® is a registered Trademark © 2021 Sanoculis LTD. MIMS® is a CE marked device (under MDD 93/42/EEC). MIMS® is an investigational device, limited by Federal (Or United States) law to investigational use.

Made By
Guided by

This site uses cookies to improve visitor experience and analyze web traffic. We may share usage data with analytics partners to enhance and optimize. By clicking accept, you consent to store on your device technologies described in our privacy policy and terms of use. Thank you. privacy policy & terms of use